Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akash Patnaik

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Urologic Oncology|December 4, 2018
Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapyBrian Olson, Akash Patnaik
Oncoscience|January 19, 2018
Neutrophils and anti-cancer immunity: a paradigm shift in cancer immunotherapyRebecca Sturey, Akash Patnaik
Journal of Virology|February 28, 2002
In vivo interference of Rous sarcoma virus budding by cis expression of a WW domainAkash Patnaik, John W Wills
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2010
New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPKGiorgia Zadra, Carmen Priolo, Akash Patnaik, et al.
Vaccines|February 12, 2021
Targeting Innate Immunity in Cancer TherapySrikrishnan Rameshbabu, Brian W Labadie, Anna Argulian, et al.
Cancer Discovery|October 13, 2018
Mouse Models for Cancer Immunotherapy ResearchBrian Olson, Yadi Li, Yu Lin, et al.
Cell Metabolism|September 3, 2008
PI3K enters beta-testingAdam J Shaywitz, Kevin D Courtney, Akash Patnaik, et al.
Cancer Discovery|November 26, 2011
The APL paradigm and the "co-clinical trial" projectCaterina Nardella, Andrea Lunardi, Akash Patnaik, et al.
Journal of Virology|February 28, 2002
Budding of equine infectious anemia virus is insensitive to proteasome inhibitorsAkash Patnaik, Vincent Chau, Feng Li, et al.
JCO Precision Oncology|March 30, 2023
Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate CancerNatalie Reizine, Samantha Socco, Eric Weng, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Urologic Oncology|December 4, 2018
Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapyBrian Olson, Akash Patnaik
Oncoscience|January 19, 2018
Neutrophils and anti-cancer immunity: a paradigm shift in cancer immunotherapyRebecca Sturey, Akash Patnaik
Journal of Virology|February 28, 2002
In vivo interference of Rous sarcoma virus budding by cis expression of a WW domainAkash Patnaik, John W Wills
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2010
New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPKGiorgia Zadra, Carmen Priolo, Akash Patnaik, et al.
Vaccines|February 12, 2021
Targeting Innate Immunity in Cancer TherapySrikrishnan Rameshbabu, Brian W Labadie, Anna Argulian, et al.
Cancer Discovery|October 13, 2018
Mouse Models for Cancer Immunotherapy ResearchBrian Olson, Yadi Li, Yu Lin, et al.
Cell Metabolism|September 3, 2008
PI3K enters beta-testingAdam J Shaywitz, Kevin D Courtney, Akash Patnaik, et al.
Cancer Discovery|November 26, 2011
The APL paradigm and the "co-clinical trial" projectCaterina Nardella, Andrea Lunardi, Akash Patnaik, et al.
Journal of Virology|February 28, 2002
Budding of equine infectious anemia virus is insensitive to proteasome inhibitorsAkash Patnaik, Vincent Chau, Feng Li, et al.
JCO Precision Oncology|March 30, 2023
Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate CancerNatalie Reizine, Samantha Socco, Eric Weng, et al.
Pageof 5